Among the Radical Pharma Scenario proposals were to replace intellectual property obligations in the WTO TRIPS accord and trade agreements with multilateral agreements on funding medical R&D, and to reform the incentive systems by replacing patent monopolies with cash prizes. Love and Hubbard and also proposed systems of "competitive intermediaries" to manage funding for open science projects. Working with artists and activists such as Ted Byfield, Alan Toner, and Jamie King, in 2002 Love proposed the Blur/Banff model for supporting artists who recorded music. In 2003, Love encouraged colleagues to consider the reform of WIPO, the UN specialized agency for intellectual property. From 2003 to 2007, the WIPO mission and work program were significantly reshaped, as WIPO adopted a new "Development Agenda," blocked progress on a treaty for broadcasting organizations and launched new work programs on limitations and exceptions to copyrights and patents. Also in 2003, Love worked with several developing country governments, including Malaysia, Indonesia, Zambia and Mozambique on the granting of compulsory licenses on patents for antimalarial drugs. In 2003, the South Africa Competition Commission hired Love and the Consumer Project on Technology to evaluate a compulsory licensing request by Hazel Tau and the South Africa Treatment Access Campaign (TAC). The Competition Commission staff found that GSK and Boehringer were in violation of three sections of South Africa competition laws, leading to licenses on patents for several suppliers of generic AIDS drugs. In 2004, working with the Trans Atlantic Consumer Dialogue (TACD), Love organized meeting on access to knowledge for essential learning tools and on the Future of WIPO. During this period, love coined the term a2k, as a community brand for the eclectic Access for Knowledge movement that had been built out of the WIPO reform efforts. In 2004 and 2005, Love worked with Tim Hubbard and others on two separate initiatives to propose new treaty paradigms for intellectual property and innovation. The first was a proposal for a global treaty on medical research and development that would replace blinding norms on patents and other intellectual property rights for medicines. The second was a comprehensive access to knowledge treaty. In 2005, Representative Bernie Sanders introduced the first of several "Medical Innovation Prize Fund" bills designed to eliminate drug monopolies, one of the reforms coming out of the 2002 Aventis scenario sessions. The 2005 prize fund bill, which was drafted in 2004, created a large fund, set at 50 basis points of US GDP, to reward developers of new drugs, on the basis of "the incremental therapeutic benefit" of a product, benchmarked against existing therapies, subject to set asides in the fund for orphan drugs and national and global public health priorities.